Marinobufogenin is a bufadienolide cardiotonic steroid found in toad venom and produced endogenously in mammals. It acts as a potent inhibitor of the Na⁺/K⁺-ATPase pump, influencing sodium and potassium ion transport across cell membranes. Research primarily focuses on its pathophysiological roles in cardiovascular conditions, including hypertension, preeclampsia, heart failure, and vascular fibrosis, where elevated levels contribute to sodium retention, vasoconstriction, and increased blood pressure. It is also studied for potential anti-cancer properties, as it can induce apoptosis and inhibit proliferation in certain cancer cell lines through effects on cellular signaling pathways. Additionally, its involvement in metabolic and inflammatory processes is under investigation. While components containing bufadienolides have historical use in traditional medicine, marinobufogenin itself requires further research to clarify its mechanisms, biomarkers, and any therapeutic applications, given its toxicity profile.